BET bromodomain inhibitors are primarily used in the field of oncology for their ability to target and disrupt the function of BET proteins, which play a critical role in the regulation of gene expression. By inhibiting these proteins, the compound can suppress the transcription of genes involved in cancer cell proliferation and survival, making it a promising therapeutic agent for various types of cancers, including leukemia, lymphoma, and solid tumors. Additionally, it is being explored for its potential in treating inflammatory diseases and cardiovascular conditions, as BET proteins are also implicated in the regulation of inflammatory and fibrotic pathways. Research is ongoing to further understand its efficacy and optimize its use in clinical settings.